Abstracts tagged "fibromyalgia"

Abstract Number: LB03 • ACR Convergence 2025
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
Leslie Crofford¹, Dana Dailey², Barbara Van Gorp², Carol Vance², Andrew Post³, Ruth Chimenti², Ezgi Yarasir², Elizabeth Johnson¹, Kari Vance², Bridget Zimmerman², Fangfang Jiang², David-Erick Lafontant², Maxine Koepp², Dixie Ecklund², Emine Bayman² and Kathleen Sluka², ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²University of Iowa, Iowa City, Iowa, ³Grand Valley State University, Grand Rapids, Michigan
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain that is often exacerbated by movement. FM is associated with enhanced central pain transmission, while transcutaneous…
Abstract Number: 1435 • ACR Convergence 2025
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Denis Poddubnyy¹, Victoria Navarro-Compan², Neil Basu³, Mohammad Naffaa⁴, Tianming Gao⁵, Christopher Saffore⁶, Jamie Urbanik⁷, Bhumik Parikh⁸, Peter Taylor⁹ and Philip J. Mease¹⁰, ¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, ⁵AbbVie, North Chicago, IL, ⁶AbbVie Inc., waukegan, IL, ⁷AbbVie, Grayslake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹University of Oxford, Oxford, United Kingdom, ¹⁰Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
Abstract Number: 1014 • ACR Convergence 2025
Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank
Sung-A Kim, Gary Macfarlane and Marcus Beasley, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: The diagnosis of fibromyalgia (FM) is challenging due to its reliance on patient-reported symptoms, the absence of definitive biomarkers, and numerous overlapping comorbidities. Discrepancies…
Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Gilad Halpert¹, Yair Dankner², Eri Govrin¹, Abdulla Watad³, Omer Gendelman¹, Shlomo Segev¹, Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Shenkar College of Engineering and Design, Ramar Gan, Israel, ³Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
Abstract Number: 0814 • ACR Convergence 2025
Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Annie Brink¹, Johan Karlsson Wallman², Jon T Einarsson¹, Meliha Kapetanovic¹, Elisabeth Mogard¹, Elisabet Lindqvist¹, Carmen Roseman¹, Kristina Lend³, Merete Hetland⁴, Mikkel Ostergaard⁵, Kim Horslev-Petersen⁶, Dan Nordstrom⁷, Tuulikki Sokka-isler⁸, Bjorn Gudbjornsson⁹, Gerður María Gröndal⁹, Marte Heiberg¹⁰, Espen Haavardsholm¹⁰, Michael Nurmohamed¹¹, Anna Rudin¹², Ronald van Vollenhoven¹³, Till Uhlig¹⁰, Jon Lampa¹⁴ and Tor Olofsson², ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ³Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ⁶Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁷Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁸Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, ⁹Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹¹Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁴Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
Abstract Number: 1254 • ACR Convergence 2025
Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
Lesley Arnold¹, Zhao Yang², Parul Houston², Todd Grinnell² and Daniel Clauw³, ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²Axsome Therapeutics, Inc, New York, NY, ³Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing which substantially impairs daily function and quality of life. Approved…
Abstract Number: 0534 • ACR Convergence 2025
Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort
Clementina López Medina¹, Sylvie Chevret², Cedric Lukas³, Anna Molto⁴ and Maxime Dougados², ¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ²Université Paris-Cité, Paris, France, ³CHU Montpellier, Montpellier, France, ⁴Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Concomitant fibromyalgia (FM) can be suspected in patients (pts) with axial SpA (axSpA) using the Fibromyalgia Rapid Screening Tool (FiRST).The objective of this study…
Abstract Number: 1245 • ACR Convergence 2025
Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
Rubab Rizwan, Sehneet Grewal, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, poughkeepsie, NY
Background/Purpose: Fibromyalgia is a chronic condition marked by widespread pain that can significantly reduce a patient’s quality of life. While low-dose naltrexone (LDN) has emerged…
Abstract Number: 0225 • ACR Convergence 2025
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Juan Schmukler¹, Tengfei Li² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
Abstract Number: 1244 • ACR Convergence 2025
PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
Rosemary Hollick¹, Marcus Beasley¹, Ernest Choy², Caroline Cupit³, Debra Dulake¹, Teresa Finlay³, Louise Locock¹, Paul McNamee¹, Catherine Pope³, Elaine Wainwright¹, David Williams⁴ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University of Michigan, Michigan
Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…
Abstract Number: 0197 • ACR Convergence 2025
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…
Abstract Number: 1242 • ACR Convergence 2025
Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Robert Katz¹, Alexandra Katz Small², Edwin Moore³ and Seth Adler⁴, ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, CHICAGO, IL, ³University of Illinois Urbana Champaign, CHICAGO, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a multifaceted disorder defined by chronic widespread pain, sleep disruption, fatigue, and cognitive difficulties. Although the predominant theory behind FM pathogenesis…
Abstract Number: 1243 • ACR Convergence 2025
Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
Robert Katz¹ and Alexandra Katz Small², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, CHICAGO, IL
Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, cognitive disturbances, and poor sleep. Despite accumulating evidence of immune involvement, a…
Abstract Number: 1237 • ACR Convergence 2025
Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
Michael Rosenbluth¹, Yifei Dai¹, Dianne Shumay¹ and Andrea Chadwick², ¹Swing Therapeutics, San Francisco, CA, ²University of Kansas School of Medicine, Kansas City, KS
Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due…
Abstract Number: 1236 • ACR Convergence 2025
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Michael Kaplan¹, Alexandra Canori², Rebecca Howard², Talia Torkian³, Rebecca Pietro¹, Gabriela Santiago-Pichardo¹, Daniel Clauw⁴, David Putrino², Yousaf Ali¹, Laura Tabacof² and Trung Ngo⁵, ¹Division of Rheumatology, Mount Sinai Hospital, New York, ²Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Icahn School of Medicine at Mount sinai, New York, ⁴Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁵RECOVER Injury Research Centre, The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Queensland, Australia
Background/Purpose: Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are prototypical nociplastic disorders marked by centralized pain & fatigue, respectively. Nociplastic symptoms — such as…

1
2
3
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].